

Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")

Launch of SLE1500 Non-Invasive Ventilator
Strengthens portfolio and expands access to neonatal respiratory market

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering best-in-class, specialist neonatal intensive care medical devices, announces the launch of the SLE1500, the latest addition to its specialist neonatal ventilator range. The SLE1500 is a compact respiratory support system that provides non-invasive ventilation ("NIV") modes to meet the needs of the smallest and most vulnerable neonatal patients requiring respiratory support, helping to protect their fragile lungs.

NIV is considered the gold standard of care for preterm infants with respiratory distress syndrome (RDS)¹ and is gradually becoming the first choice for respiratory support². The SLE1500 has been specifically designed to meet the special needs of some of the most vulnerable babies, starting in the delivery room, to augment their first breaths of life and as they move through their stay in neonatal intensive care. The SLE1500 system offers six non-invasive delivery options in one machine; nasal Continuous Positive Airway Pressure (nCPAP) both flow and pressure controlled, high flow oxygen therapy, and manual flow for use with therapies like bubble CPAP, all of which can be augmented with Pulse Oximetry (SpO₂) and / or automatic oxygen control (auto FiO₂) through OxyGenie®. OxyGenie®, the Company's patented algorithmic oxygen controller, provides second by second control of oxygenation, allowing the baby to spend more time in its target oxygen saturation and staff to spend more time caring for the infant, thus improving outcomes.³

Neil Campbell, CEO of Inspiration Healthcare, commented: "We are delighted to extend our differentiated best-in-class ventilator product range with the launch of our new SLE1500 respiratory support system, which will enable us to support more babies. The need for non-invasive ventilation is paramount for the effective treatment and care of the smallest and most vulnerable neonates. The SLE1500 strengthens our ventilator product range and complements our range of respiratory consumables allowing us to offer better solutions to our customers worldwide.

"Our initial launch is focused on the UK and Australia, with other market introductions due to follow, subject to regulatory approvals. We are excited about the potential for the SLE1500, which demonstrates a key part of our growth strategy and our continued R&D commitment to pioneer innovative technologies to help save lives daily."

1. Non-invasive ventilatory support in neonates: An evidence-based update [Paediatric Respiratory Reviews Volume 44](#), December 2022, Pages 11-18 Ramadan A. Mahmoud, Gerd Schmalisch, Abhishek Oswal, Charles Christoph Roehr

2. Non-invasive Respiratory Support in Neonates: A Review of Current Evidence and Practices [Indian J Pediatr](#). 2021; 88(7): 670–678. [Rajendra Prasad Anne](#)¹ and [Srinivas Murki](#)

3. The effect of automated oxygen control on clinical outcomes in preterm infants: a pre- and post-implementation cohort study [European Journal of Pediatrics](#) (2021) 180:2107–2113 H. H. Salverda, N. J. Oldenburger¹ & M. Rijken, S. C. Pauw & P. A. Dargaville, A. B. te Pas¹

For further information, please contact:

Inspiration Healthcare Group plc
Neil Campbell, Chief Executive Officer
Alan Olby, Chief Financial Officer

Tel: +44 (0)330 175 0000

Walbrook PR Ltd (Media and Investor Relations)

Anna Dunphy
Stephanie Cuthbert
Louis Ashe-Jepson

Tel: +44 (0)20 7933 8780 or
inspirationhealthcare@walbrookpr.com
Mob: +44 (0) 7876 741 001
Mob: +44 (0) 7796 794 663
Mob: +44 (0) 7747 515 393

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in neonatal intensive care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

The Company has key own brand products that can be used within the first days of life to help premature and sick babies; helping resuscitation and stabilisation in the first moments of life through to preventing brain damage and both invasive and non-invasive respiratory support in terms of capital equipment and disposable medical devices. Additionally, the Company has its own range of products for maintaining normothermia pre, during and post-surgery.

Since September 2019, the Company has acquired Vio Holdings a designer, manufacturer and supplier of single use respiratory products and sterile medical consumables and S.L.E., a leading designer, manufacturer and global provider of neonatal ventilation products. The Group generates approximately 58% of its revenues from export markets and more than half of its revenues come from its own-branded products.

With product availability actively promoted to over 80 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the UK and Ireland, the Group has direct sales teams selling Group Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

The Group operates from various sites in the UK for R&D, Marketing and operations with manufacturing based in Croydon (south London) and Hailsham (East Sussex). The Group's Head Office is located in Crawley, a short distance from London's Gatwick Airport.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEASFFEEDDFFA